PT2796550T - Novo anticorpo ctgf anti-humano - Google Patents

Novo anticorpo ctgf anti-humano

Info

Publication number
PT2796550T
PT2796550T PT128607421T PT12860742T PT2796550T PT 2796550 T PT2796550 T PT 2796550T PT 128607421 T PT128607421 T PT 128607421T PT 12860742 T PT12860742 T PT 12860742T PT 2796550 T PT2796550 T PT 2796550T
Authority
PT
Portugal
Prior art keywords
novel anti
ctgf antibody
human ctgf
human
antibody
Prior art date
Application number
PT128607421T
Other languages
English (en)
Portuguese (pt)
Inventor
Iwasaki Shoji
Moriya Ryuichi
Yoshino Masayasu
Takakura Koji
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PT2796550T publication Critical patent/PT2796550T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT128607421T 2011-12-22 2012-12-21 Novo anticorpo ctgf anti-humano PT2796550T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011281811 2011-12-22

Publications (1)

Publication Number Publication Date
PT2796550T true PT2796550T (pt) 2018-04-18

Family

ID=48668601

Family Applications (1)

Application Number Title Priority Date Filing Date
PT128607421T PT2796550T (pt) 2011-12-22 2012-12-21 Novo anticorpo ctgf anti-humano

Country Status (16)

Country Link
US (1) US9587015B2 (enExample)
EP (1) EP2796550B1 (enExample)
JP (1) JP6040943B2 (enExample)
KR (1) KR20140107507A (enExample)
CN (1) CN104011206B (enExample)
AR (1) AR089425A1 (enExample)
BR (1) BR112014015405A2 (enExample)
CA (1) CA2859627A1 (enExample)
EA (1) EA029290B1 (enExample)
ES (1) ES2665851T3 (enExample)
IN (1) IN2014CN04615A (enExample)
MX (1) MX345019B (enExample)
PL (1) PL2796550T3 (enExample)
PT (1) PT2796550T (enExample)
TW (1) TW201333034A (enExample)
WO (1) WO2013094723A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109824777A (zh) * 2019-03-15 2019-05-31 辽宁何氏医学院 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
CA3142092A1 (en) * 2019-06-04 2020-12-10 Jiangsu Hengrui Medicine Co., Ltd. Anti-connective tissue growth factor antibody and application thereof
US20230416352A1 (en) * 2020-12-03 2023-12-28 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-connective tissue growth factor antibody
JPWO2023238845A1 (enExample) 2022-06-07 2023-12-14
AU2023373601A1 (en) 2022-10-31 2025-04-03 Astellas Pharma Inc. Antibody-drug conjugate containing a toll-like receptor 7/8 dual agonist compound
WO2024188179A1 (zh) * 2023-03-10 2024-09-19 上海济煜医药科技有限公司 一种靶向ctgf的抗体或其抗原结合片段及其应用
WO2025047848A1 (ja) 2023-08-30 2025-03-06 アステラス製薬株式会社 IdeZ改変体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8808645U1 (de) 1988-07-06 1988-08-25 Hofer, Daniel, 7730 Villingen-Schwenningen Anzeigeeinrichtung für Feuerlöscher
DE69433422T2 (de) 1993-03-11 2004-09-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Monoklonaler anti-hiv antikörper
JP4537507B2 (ja) 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
US6562618B1 (en) 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
US7115390B1 (en) 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
MXPA01005949A (es) 1998-12-14 2002-09-18 Univ Miami Fragmentos de factor de crecimiento de tejido conectivo y metodos y usos de los mismos.
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
JP2009067678A (ja) * 2005-12-07 2009-04-02 Nihon Nosan Kogyo Kk 結合組織増殖因子に対する抗体又はそれを含む組成物
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Also Published As

Publication number Publication date
PL2796550T3 (pl) 2018-08-31
CN104011206B (zh) 2017-03-08
MX2014007681A (es) 2014-11-25
EA201491240A1 (ru) 2014-11-28
JP6040943B2 (ja) 2016-12-07
BR112014015405A2 (pt) 2017-06-13
EP2796550A4 (en) 2015-08-19
WO2013094723A1 (ja) 2013-06-27
TW201333034A (zh) 2013-08-16
MX345019B (es) 2017-01-11
JPWO2013094723A1 (ja) 2015-04-27
AR089425A1 (es) 2014-08-20
EA029290B1 (ru) 2018-03-30
US9587015B2 (en) 2017-03-07
EP2796550B1 (en) 2018-02-28
CN104011206A (zh) 2014-08-27
IN2014CN04615A (enExample) 2015-09-18
KR20140107507A (ko) 2014-09-04
ES2665851T3 (es) 2018-04-27
US20140343258A1 (en) 2014-11-20
EP2796550A1 (en) 2014-10-29
CA2859627A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
ES3065861T3 (en) Interleukin-31 monoclonal antibody
IL259826A (en) Anti-alphabetatisiar antibody
ZA201307983B (en) Anti-b7-h3 antibody
IL220404A (en) Antiseptic antibodies
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
HUE037811T2 (hu) Alfa-szinukleint felismerõ humanizált antitestek
SG11201402283PA (en) Anti il-36r antibodies
ZA201400741B (en) Novel anti-human ngf antibody
PL2796550T3 (pl) Nowe przeciwciało przeciwko ludzkiemu CTGF
TWI563004B (en) Anti-hxcr1 antibody
PT2695897T (pt) Novo anticorpo anti-receptor de il-23 humano
EP2694539A4 (en) POLYCLONAL ANTIBODY COMPOSITIONS
EP2707392A4 (en) MONOCLONAL ANTIBODY FOR ACETYLAMANTADINE
PL2821416T3 (pl) Nowe przeciwciało przeciwko ludzkiemu receptorowi IL-23
EP2714074A4 (en) ANTIBODIES AGAINST EMR1